We analyzed the prognostic impact of the most frequent genetic abnormalities detected by fluorescence in situ hybridization in 101 patients with multiple myeloma, who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after melphalan/fludarabine-based reduced conditioning. The incidences of abnormalities in the present analysis were as follows: del(13q14) (61%), t(11;14)(q13;q32) (14%), t(4;14)(p16.3;q32) (19%), MYC-gain gains (8q24) (21%), del(17p13) (16%) and t(14;16)(q32;q23) (5%). None of the patients had t(6;14)(p25;q32). The overall complete remission (CR) rate was 50% with no differences between the genetic abnormalities except for patients with del(17p13) who achieved less CR (7 vs 56%; P ¼ 0.001). Univariate analysis revealed a higher relapse rate in patients aged 450 years (P ¼ 0.002), patients with del(13q14) (P ¼ 0.006) and patients with del(17p13) (P ¼ 0.003). In multivariate analyses, only del(13q14) (HR: 2.34, P ¼ 0.03) and del(17p13) (HR: 2.24; P ¼ 0.04) significantly influenced the incidence of relapse, whereas for event-free survival, only age (HR 2.8; P ¼ 0.01) and del(17p13) (HR: 2.05; P ¼ 0.03) retained their negative prognostic value. These data show that del(17p13) is a negative prognostic factor for achieving CR as well as for event-free survival after HSCT. Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies.
Introduction
Beside biological markers such as b 2 -microglobulin and serum albumin, chromosomal abnormalities have been shown to be a useful marker for prognostic evaluation in patients with multiple myeloma. [1] [2] [3] Owing to the low proliferative activity of malignant plasma cells, conventional cytogenetic analysis cannot be performed in all patients, but fluorescence in situ hybridization (FISH) allows detection of specific chromosomal changes in noncycling interphase cells, which can help assess patients' prognosis. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The prognostic impact of chromosomal abnormalities has been shown for conventional chemotherapy as well as for autologous stem cell transplantation. 2, 4, 5, [7] [8] [9] [10] [12] [13] [14] [15] 17, 18 Only very few data of cytogenetic abnormalities and their impact on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) exist. 19 Since the introduction of reduced-intensity conditioning, which led to a substantial reduction of treatment-related mortality, allogeneic HSCT is now a reasonable treatment approach in multiple myeloma, even in elderly patients, and in patients with unrelated donors. 20, 21 The most promising approach is a tandem-autologous-allogeneic (reduced-intensity) transplantation that induces a high rate of complete remission (CR) with a relatively low treatment-related mortality. 20, 22, 23 However, the long-term role of reduced-intensity conditioning followed by allogeneic HSCT in the treatment of myeloma patients remains to be determined. Two completed randomized studies comparing autologous-allogeneic-transplantation with tandem-autologous stem cell transplantation have revealed inconclusive results. 22, 24 In the French study, only high-risk patients, defined by high b 2 -microglobulin and presence of del(13q14) were included, and no benefit could be shown for autologous-allogeneic-tandem approach. In the Italian study, which included all patients up to the age of 65 years irrespective of chromosomal abnormalities or other known risk factors, a significant survival benefit could be shown for the patients treated with allogeneic HSCT. The results of the Blood and Marrow Transplant Clinical Trial Network prospective study comparing autologous-autologous with autologous-allogeneic are still pending. The influence of cytogenetic abnormalities on outcome after allogeneic HSCT might help to define the population of myeloma patients, which will benefit from an allograft.
In a previous analysis, we could show that del(13q14) detected by FISH negatively influenced survival after reduced intensity HSCT, 19 however, in this analysis only del(13q14) was investigated. More recent data, especially after autologous transplantation, suggested that del(13q14) alone does not shorten overall survival, but its association with other abnormalities such as del(17p13) or t(4;14) reduced survival probability. 4, 7, 8, 12, 13 In the current study we performed a comprehensive analysis of different interphase-FISH analyses ((del(13q14), del(17p13) (P53), 8q24 (MYC), t(4;14), t (11;14) , t(14;16) and t(6;14)) in 101 patients who were homogeneously treated within a melphalan/ fludarabine-based allogeneic HSCT treatment protocol. 20, 25 Patients, materials and methods
Patients' characteristics
One hundred-one patients with advanced multiple myeloma were included in the study. All patients were treated within two different prospective dose-reduced allogeneic treatment protocols consisting of melphalan (100-150 mg/m 2 ) and fludarabine (90-180 mg/m 2 ) with (n ¼ 80) or without (n ¼ 21) anti-thymocyte globulin (ATG; Fresenius, Gräfelfing, Germany). One trial was conducted in Germany and Israel, and the other one in Spain. In total 34 of the patients received graft from their matched-related and 67 patients from a matched-unrelated donor. To be included, patients were required to have a sufficient cardiac function (ejection fraction 430%), a creatinine-clearance level of 430 ml/min, a lung-diffusion capacity of at least 50% and liver transaminases o3 times the upper limit of normal. The median age of the patients was 52 years (range: 28-68 years). There were 59 male and 42 female patients. The median b 2 -microglobulin level at transplantation was 2.4 mmol/l (range: 0.2-12.9). The median number of prior chemotherapy cycles was six (range: 2-26). Ninety-seven patients had received a prior autograft, and only four patients received allogenic-transplant without a preceding autograft. Altogether 17 patients had received two or more autografts; 50 patients had experienced relapse to a prior autologous transplantation and 51 were treated within an autologous-allogeneic-tandem approach. The disease status prior to transplantation was CR (n ¼ 3), partial remission (n ¼ 69), minor remission (n ¼ 1), no change (n ¼ 2) and progressive disease (n ¼ 26). The source of stem cells was peripheral blood in 97 patients, and only 4 patients received bone marrow as stem cells. No manipulation of the graft was performed. Ten patients were also included and reported in a previous analysis. 19 The median follow-up of the surviving patients was 33 months (range: 3-73). Major characteristics of the patients are shown in Table 1 .
Materials and methods
FISH analysis was performed either on purified plasma cells or by cytoplasma-immunoglobulin staining (cIg-FISH): cIg-FISH was performed as previously described. 19 FISH probes mapping to chromosome bands 13q14 (D13S25), 8q24 (MYC), and 17p13.1 (P53), as well as probes for the detection of the translocations t(4;14), t(11;14) and t(14;16) were purchased from Vysis (Downers Grove, IL, USA). Probes for the detection of t(6;14)(p25;q32) were not commercially available and therefore prepared with probes for chromosome 14 (y6 and cosa1) and chromosome 6 (1077H22, 856G1 and 416J7) from BACPAC resources center at the Children's Hospital Oakland Research Institute), combining the break apart assay for the IGH locus (14q32) with probes hybridizing to the region 6p25. The Spanish patients with IGH translocation were explored first for t(11;14)(q13;p32) (LSI IGH/CCND1, dual fusion translocation probe and subsequently analyzed for t(4;14)(p16;q32) (4p-BAC clones L75b9, L190b4,L96a2,PAC 184d6:14q32-VH:cosmid yIgH6-9,CH: BAC B158 A2) and finally for t(14;16)(q32;q23)(16q23-BAC clones 356D21, 484H2, 10205 and 10206). Rafael Fonseca from the Mayo Clinic (Scottsdale, AZ, USA) kindly provided the probes for the last two translocations. In some patients, a combined morphologic and FISH analysis was performed as recently described. 26 FISH diagnostics were performed either at diagnosis (n ¼ 53) or before allogeneic stem cell transplantation (n ¼ 47). In one patient, FISH analysis was performed on residual myeloma cells after allogeneic stem cell transplantation.
Statistics
Event-free survival (EFS) and overall survival were calculated from date of allogeneic HSCT to the respective events. Death from whatever cause and relapse/progression was counted as an event in case of EFS. All time-to-event curves were estimated according to the method of Kaplan and Meier and compared univariately using the logrank test. Nonrelapse mortality and relapse/progression were calculated using cumulative incidence 
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Abbreviations: CR, complete remission; FISH, fluorescence in situ hybridization; HLA, human lymphocyte antigen; MR, minor remission; PD, progressive disease; PR, partial remission; SD, stable disease.
Genetic abnormalities and allogeneic HSCT in myeloma G Schilling et al estimates. Multivariate analyses were performed with a Cox regression proportional hazard model, initially including all factors with a P-value of no more than 0.1 in the univariate analysis, and using a stepwise backward approach for model reduction. Comparison of relapse was evaluated by w 2 -test. All tests were two-sided. A P-value of less than 0.05 was considered significant. The statistical analysis was performed with SPSS software package.
Results

FISH analysis
Del(13q14) was observed in 62/101 patients (61%), and as a single abnormality 13/32 (41%). Translocation t(11;14) was seen in 11/80 patients (14%) and was associated with del(13q) in 7 patients (64%). Translocation t(4;14) was observed in 16/86 patients (19%) and was mostly associated with del(13q14) (14/16), whereas association with 17p translocation was only seen in 2 patients (13%). Loss of 17p was seen in 16 patients (16%) and frequently associated with occurrence of del(13q14) (15/16). MYC-gain gains were seen in 17 patients (17%) and frequently associated with del(13q14) (14/17). Translocation t(14;16) was seen only in four patients (4%), and three out of these four patients had del(13q14). Translocation t(6;14) was not observed in a single patient and therefore excluded for further analysis.
Response to treatment
Response to treatment was evaluated according to the European Group for Blood and Marrow Transplantation criteria published by Bladé et al. 27 CR was noted in 45/89 (51%) of the patients. No difference in achievement of CR was seen for patients with del(13q14), MYC-gain gains, t(4;14), t(11;14) and t(4;16), whereas patients with del(17p13) had a significant lower rate of CR in comparison to others (7 vs 58%; P ¼ 0.001). The occurrence of acute graft-versus-host disease (GvHD) did not influence the incidence of CR (P ¼ 0.9) or survival (P ¼ 0.5) ( Table 2) .
Relapse
During follow-up, 38 relapses or progressions were observed. In a univariate analysis, a statistically higher relapse incidence at 4 years was seen for patients older than 50 years of age (65 vs 45%; P ¼ 0.02), and for patients harboring del(13q14) (70 vs 36%; P ¼ 0.006), or del(17p13) (73 vs 54%; P ¼ 0.003). A borderline significance could be observed for patients with failure to a prior autograft (59 vs 49%; P ¼ 0.08). No difference was seen for t(4;14), t(11;14), t(14;16), cmyc, any abnormality or del(13q14) as single abnormality. Furthermore, no influence on relapse incidence was seen for remission status prior transplantation, donors' sex and b 2 -microglobulin (Table 3) . In a multivariate analysis, del(13q14) (HR: 2.34) (95% CI: 1.06-5.15) (P ¼ 0.03) and del(17p13) (HR: 2.24) (95% CI: 1.02-4.92) (P ¼ 0.04) emerged as independent factors for higher relapse incidence (Table 4) .
Treatment-related mortality
The treatment-related mortality for the whole study population was 21% at 1 year. The only significant factor for higher treatment-related mortality was age above 50 years (33 vs 13%; P ¼ 0.03).
Event-free survival
No significant impact on EFS at 4 years was seen for del(13q14), t(4;14), t(11;14), t(14;16), MYC-gain, higher b 2 -microglobulin (43,5 mmol/l), unrelated donor and any FISH abnormality. A trend for lower EFS at 4 years was seen for patients who failed to a prior autograft (33 vs 52%; P ¼ 0.09). A significant influence Table 2 Results
Remission after allografting (evaluable: n ¼ 89)
Abbreviations: CR, complete remission; GvHD, graft-versus-host disease; MR, minor remission; PD, progressive disease; PR, partial remission; SD, stable disease. Genetic abnormalities and allogeneic HSCT in myeloma G Schilling et al was seen for del(17p13) (28 vs 43%; P ¼ 0.02), and for higher age (450 years) (25 vs 63%; P ¼ 0.001) ( Table 3) . In a multivariate analysis, higher age (HR: 2.8; P ¼ 0.01), and presence of del(17p13) (HR: 2.0; P ¼ 0.03), remained independent significant factors for worse EFS (Table 4 ; Figures 1-3 ).
Overall survival
No significant impact on overall survival after 4 years was seen for del13(q14), t(4;14), t(11;14), t(14;16), unrelated donors and any FISH abnormalities. A trend for worse overall survival was seen for patients with del(17p13) (P ¼ 0.07) or MYC-gain (P ¼ 0.08). A significant influence on shorter overall survival was seen for patients with higher b 2 -microglobulin (43.5 mmol/l) (P ¼ 0.04), and for higher age (450 years) (P ¼ 0.001) ( Table 3 ). As the numbers of patients with known b 2 -microglobulin was only 79, this variable was not included in the multivariate analysis. In a multivariate analysis, only age 450 years remained an independent significant factor for a shorter overall survival (HR: 2.9; P ¼ 0.002) ( Table 4 ; Figures 1-3 ).
Influence of failure to a previous allograft
In contrast to previous studies, 28 patients who relapsed to a prior autograft showed only a trend for decreased EFS (33 vs 52%, P ¼ 0.09). Patients with del(13q) (n ¼ 61) and/or del(17p) (n ¼ 16) had only a trend for improved survival (P ¼ 0.09 and P ¼ 0.5), if they received allogeneic stem cell transplantation Table 4 Multivariate analysis of relapse, EFS and OS at 4 years after allogeneic stem cell transplantation before failure to an autograft, whereas patients with t(4;14) (n ¼ 15) had an improved EFS, if they were transplanted without relapse to an autograft (P ¼ 0.02). We additionally performed a cytogenetic subanalysis in patients with and without failure to a prior autograft. As for the entire study group in patients with failure to a previous autograft (n ¼ 51) neither del(13q) (P ¼ 0.26) nor t(4;14) (P ¼ 0.23) but del(17p13) (P ¼ 0.05) influenced EFS in this subgroup of patients. In patients without relapse to a previous autograft (n ¼ 51) neither del(13q) (P ¼ 0.6) nor del(17p13) (P ¼ 0.3) and t(4;14) (P ¼ 0.1) influenced EFS. However, it is of note that patients with t(4;14) had a trend for an improved EFS (85 vs 50%), but the number is too small (n ¼ 7) to draw valid conclusions.
Discussion
This comprehensive FISH analysis of chromosomal abnormalities and their influence on outcome after allogeneic HSCT showed that del(17p13) is a significant prognostic factor for EFS after allografting. This is mainly due to the significantly higher incidence of relapse or progression within this group of patients. Furthermore, del(17p13) is the only tested cytogenetic abnormality that achieved a significantly lower rate of CR in comparison to others or no abnormalities (7 vs 58%; P ¼ 0.001). This abnormality was seen in 16% of our series of patients, which was higher than the reported 10% incidence in other studies. 4, 7, 8, [12] [13] [14] These findings and the relatively high proportion of patients carrying del(13q) (62%) is reflecting the adverse prognoses of the patient population, referred to allogeneic HSCT. Most series reported a very short median survival between 15 and 29 months for patients with p53 deletions. 4, 8, 13 Despite the worse outcome of patients harboring del(17p13), the observed EFS of 28% at 4 years compares favorably to the recent reported 10% EFS for patients who received autologous stem cell transplantation, 4 but indicates a strong need for further improvement in this group of high-risk patients.
In contrast to our previous study, del(13q14) remained a significant factor only for relapse, but not for EFS and overall survival. This might be explained by the fact that in the previous study more advanced patients (50% refractory) were included, whereas in the current trial only 28% of the patients were refractory prior to allografting. Furthermore, in the previous study only del(13q14) was investigated, whereas in the present study 15/16 patients carrying del(17p13) also carry del(13q14). Therefore, it is not surprising that del(13q14) as single abnormality, in contrast to del(13q14) plus others, has also lost its negative impact on EHS and overall survival. This is in accordance with recent publications reporting that del(13q14) alone is not any more a negative prognostic factor after autografting. 4, 13 These reports showed that del(17p13) and t (4;14) are in a multivariate analysis the only chromosomal abnormalities that independently influenced survival. The major finding of our study is that t(4;14) did not have (not even a trend) for less CRs or worse EFS or overall survival. These results suggest that the negative impact of t(4;14) might be overcome by allogeneic HSCT. The translocation t(4;14) is the second most frequent translocation to translocation t(14q32) in multiple myeloma, leading to a deregulation of two genes located at the 4p16 breakpoint, FGFR3 and MMSET.
29 About 15% of the myeloma patients carry this mutation. More recently, gene expression profile can discriminate two groups within the t(4;14)-positive patients with different outcomes, 30 but all clinical trials using FISH to detect t(4;14) have confirmed the negative prognostic impact. 4, 8, [12] [13] [14] Patients with translocation t(4;14) and low b 2 -microglobulin and high hemoglobin were reported to have better prognosis after tandem-autologous HSCT. 31 Translocation t(14;16), which is detectable in about 6-8% of myeloma patients and associated with an unfavorable outcome after autologous stem cell transplantation, 10 was not associated with less frequent CR or worse overall survival after allografting, but due to the low number of patients with this specific translocation (n ¼ 4) in our study, no definitive conclusions can be drawn. Another important factor in this current analysis was age less than 50 years, which remained a significant factor for better EFS and overall survival. This is mainly due to a lower treatment-related mortality. The treatment-related mortality of 13% and an EFS of more than 60% at 4 years indicate the need for further evaluation of allogeneic HSCT especially in this cohort of patients.
We conclude that del(17p13) is a significant factor for less CRs and shorter EFS in patients undergoing allogeneic stem cell transplantation for multiple myeloma, whereas the negative impact of t(4;14) seen after autologous stem cell transplantation can be overcome by allogeneic stem cell transplantation.
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